Brainstorm Cell Therapeutics Ownership 2024 | Who Owns Brainstorm Cell Therapeutics Now?
Institutional Ownership
18.63%
Insider Ownership
9.00%
Retail Ownership
72.38%
Institutional Holders
49.00
Brainstorm Cell Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 12.23% | 0.03% | 7,917,653 | 7,917,653 | 100.00% | 2,680,126 | Jun 30, 2024 |
| VANGUARD GROUP INC | 2.33% | - | 1,510,640 | 109,647 | 7.83% | 511,352 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.75% | - | 484,285 | 127,244 | 35.64% | 163,986 | Jun 30, 2024 |
| BLACKROCK INC. | 0.60% | - | 386,414 | -102,899 | -21.03% | 130,801 | Jun 30, 2024 |
| LIBERTY WEALTH MANAGEMENT LLC | 0.53% | 0.02% | 340,150 | - | - | 115,000 | Jun 30, 2024 |
| WEAVER CONSULTING GROUP | 0.36% | 0.03% | 234,356 | 35,000 | 17.56% | 79,330 | Jun 30, 2024 |
| ABNER HERRMAN & BROCK LLC | 0.22% | 0.01% | 145,500 | - | - | 49,000 | Jun 30, 2024 |
| STATE STREET CORP | 0.18% | - | 117,260 | 21,200 | 22.07% | 39,693,000 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.17% | - | 112,358 | 57,570 | 105.08% | 38,033,000 | Jun 30, 2024 |
| RAYMOND JAMES & ASSOCIATES | 0.17% | - | 111,285 | -2,500 | -2.20% | 37,670 | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.16% | 0.00% | 102,016 | 102,016 | 100.00% | 34,532 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.14% | 0.01% | 90,242 | - | - | 30,547 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.13% | 0.00% | 86,579 | 75,574 | 686.72% | 29,350 | Jun 30, 2024 |
| JMAC ENTERPRISES LLC | 0.10% | 0.00% | 65,430 | - | - | 22,148 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.08% | 0.00% | 49,586 | 49,586 | 100.00% | 17,000 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.07% | 0.00% | 46,754 | 16,100 | 52.52% | 15,826,000 | Jun 30, 2024 |
| MORGAN STANLEY | 0.06% | - | 36,975 | -3,123 | -7.79% | 12,516 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.04% | - | 28,811 | -299 | -1.03% | 9,752 | Jun 30, 2024 |
| JANNEY MONTGOMERY SCOTT LLC | 0.03% | - | 20,500 | - | - | 7,000 | Jun 30, 2024 |
| PROFESSIONAL FINANCIAL ADVISORS, LLC | 0.03% | 0.00% | 17,279 | - | - | 5,849 | Jun 30, 2024 |
Brainstorm Cell Therapeutics's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 12.23% of the company's total share outstanding, currently valued at $2.68M. The top 10 institutional shareholders own together 17.55% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 12.23% | 0.03% | 7,917,653 | 7,917,653 | 100.00% | 2,680,126 | Jun 30, 2024 |
| WEAVER CONSULTING GROUP | 0.36% | 0.03% | 234,356 | 35,000 | 17.56% | 79,330 | Jun 30, 2024 |
| LIBERTY WEALTH MANAGEMENT LLC | 0.53% | 0.02% | 340,150 | - | - | 115,000 | Jun 30, 2024 |
| ABNER HERRMAN & BROCK LLC | 0.22% | 0.01% | 145,500 | - | - | 49,000 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.14% | 0.01% | 90,242 | - | - | 30,547 | Jun 30, 2024 |
| SAXONY CAPITAL MANAGEMENT, LLC | 0.02% | 0.00% | 12,950 | -8,000 | -38.19% | 4,384 | Jun 30, 2024 |
| JMAC ENTERPRISES LLC | 0.10% | 0.00% | 65,430 | - | - | 22,148 | Jun 30, 2024 |
| FIRST AFFIRMATIVE FINANCIAL NETWORK | 0.02% | 0.00% | 14,293 | -985 | -6.45% | 4,838 | Jun 30, 2024 |
| PROFESSIONAL FINANCIAL ADVISORS, LLC | 0.03% | 0.00% | 17,279 | - | - | 5,849 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.08% | 0.00% | 49,586 | 49,586 | 100.00% | 17,000 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.01% | 0.00% | 7,080 | 7,080 | 100.00% | 2,397 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.13% | 0.00% | 86,579 | 75,574 | 686.72% | 29,350 | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.16% | 0.00% | 102,016 | 102,016 | 100.00% | 34,532 | Jun 30, 2024 |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 0.01% | 0.00% | 6,000 | - | - | 2,031 | Jun 30, 2024 |
| VISIONPOINT ADVISORY GROUP, LLC | 0.00% | 0.00% | 1,944 | - | - | 658 | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | 0.02% | 0.00% | 11,232 | -1,454 | -11.46% | 3,802 | Jun 30, 2024 |
| BANGOR SAVINGS BANK | 0.01% | 0.00% | 4,000 | - | - | 1,354 | Jun 30, 2024 |
| CRANBROOK WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 1,000 | - | - | 339 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.07% | 0.00% | 46,754 | 16,100 | 52.52% | 15,826,000 | Jun 30, 2024 |
| EVERSOURCE WEALTH ADVISORS, LLC | 0.00% | - | 2,128 | - | - | 728 | Jun 30, 2024 |
The largest Brainstorm Cell Therapeutics shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 7.92M shares of Brainstorm Cell Therapeutics (BCLI), representing 0.03% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 12.23% | 0.03% | 7,917,653 | 7,917,653 | 100.00% | 2,680,126 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.75% | - | 484,285 | 127,244 | 35.64% | 163,986 | Jun 30, 2024 |
| VANGUARD GROUP INC | 2.33% | - | 1,510,640 | 109,647 | 7.83% | 511,352 | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.16% | 0.00% | 102,016 | 102,016 | 100.00% | 34,532 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.13% | 0.00% | 86,579 | 75,574 | 686.72% | 29,350 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.17% | - | 112,358 | 57,570 | 105.08% | 38,033,000 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.08% | 0.00% | 49,586 | 49,586 | 100.00% | 17,000 | Jun 30, 2024 |
| WEAVER CONSULTING GROUP | 0.36% | 0.03% | 234,356 | 35,000 | 17.56% | 79,330 | Jun 30, 2024 |
| STATE STREET CORP | 0.18% | - | 117,260 | 21,200 | 22.07% | 39,693,000 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.07% | 0.00% | 46,754 | 16,100 | 52.52% | 15,826,000 | Jun 30, 2024 |
| LPL FINANCIAL LLC | 0.02% | - | 10,052 | 10,052 | 100.00% | 3,403 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.01% | 0.00% | 7,080 | 7,080 | 100.00% | 2,397 | Jun 30, 2024 |
| UBS GROUP AG | 0.01% | - | 7,110 | 4,610 | 184.40% | 2,411 | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | 0.01% | - | 5,504 | 1,465 | 36.27% | 1,000 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.00% | - | 1,492 | 492 | 49.20% | 504 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 255 | 149 | 140.57% | 86 | Jun 30, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | 0.00% | - | 364 | - | - | 123 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.02% | - | 11,994 | - | - | 4,060 | Jun 30, 2024 |
| ST GERMAIN D J CO INC | 0.00% | - | 500 | - | - | 169 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.02% | - | 10,519 | - | - | 3,576 | Jun 30, 2024 |
As of Jun 30 2024, Brainstorm Cell Therapeutics's largest institutional buyer is ARMISTICE CAPITAL, LLC. The company purchased 7.92M stocks of BCLI, valued at $2.68M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| GSA CAPITAL PARTNERS LLP | - | - | - | -111,234 | -100.00% | - | Jun 30, 2024 |
| BLACKROCK INC. | 0.60% | - | 386,414 | -102,899 | -21.03% | 130,801 | Jun 30, 2024 |
| KINGSWOOD WEALTH ADVISORS, LLC | - | - | - | -81,050 | -100.00% | - | Jun 30, 2024 |
| SOCHA FINANCIAL GROUP, LLC | - | - | - | -12,380 | -100.00% | - | Jun 30, 2024 |
| CYPRESS CAPITAL MANAGEMENT LLC (WY) | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| SAXONY CAPITAL MANAGEMENT, LLC | 0.02% | 0.00% | 12,950 | -8,000 | -38.19% | 4,384 | Jun 30, 2024 |
| MORGAN STANLEY | 0.06% | - | 36,975 | -3,123 | -7.79% | 12,516 | Jun 30, 2024 |
| RAYMOND JAMES & ASSOCIATES | 0.17% | - | 111,285 | -2,500 | -2.20% | 37,670 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 2,700 | -1,500 | -35.71% | 914 | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | 0.02% | 0.00% | 11,232 | -1,454 | -11.46% | 3,802 | Jun 30, 2024 |
| FIRST AFFIRMATIVE FINANCIAL NETWORK | 0.02% | 0.00% | 14,293 | -985 | -6.45% | 4,838 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.04% | - | 28,811 | -299 | -1.03% | 9,752 | Jun 30, 2024 |
| CORECAP ADVISORS, LLC | - | - | - | -133 | -100.00% | - | Jun 30, 2024 |
| LIBERTY WEALTH MANAGEMENT LLC | 0.53% | 0.02% | 340,150 | - | - | 115,000 | Jun 30, 2024 |
| ABNER HERRMAN & BROCK LLC | 0.22% | 0.01% | 145,500 | - | - | 49,000 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.14% | 0.01% | 90,242 | - | - | 30,547 | Jun 30, 2024 |
| JMAC ENTERPRISES LLC | 0.10% | 0.00% | 65,430 | - | - | 22,148 | Jun 30, 2024 |
| PROFESSIONAL FINANCIAL ADVISORS, LLC | 0.03% | 0.00% | 17,279 | - | - | 5,849 | Jun 30, 2024 |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 0.01% | 0.00% | 6,000 | - | - | 2,031 | Jun 30, 2024 |
| VISIONPOINT ADVISORY GROUP, LLC | 0.00% | 0.00% | 1,944 | - | - | 658 | Jun 30, 2024 |
As of Jun 30 2024, Brainstorm Cell Therapeutics's biggest institutional seller is GSA CAPITAL PARTNERS LLP. The company sold -0.11M shares of BCLI, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 12.23% | 0.03% | 7,917,653 | 7,917,653 | 100.00% | 2,680,126 | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.16% | 0.00% | 102,016 | 102,016 | 100.00% | 34,532 | Jun 30, 2024 |
| LPL FINANCIAL LLC | 0.02% | - | 10,052 | 10,052 | 100.00% | 3,403 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.01% | 0.00% | 7,080 | 7,080 | 100.00% | 2,397 | Jun 30, 2024 |
Brainstorm Cell Therapeutics's largest new institutional shareholder by number of shares is ARMISTICE CAPITAL, LLC, purchased 7.92M shares, valued at $2.68M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| GSA CAPITAL PARTNERS LLP | - | - | - | -111,234 | -100.00% | - | Jun 30, 2024 |
| KINGSWOOD WEALTH ADVISORS, LLC | - | - | - | -81,050 | -100.00% | - | Jun 30, 2024 |
| SOCHA FINANCIAL GROUP, LLC | - | - | - | -12,380 | -100.00% | - | Jun 30, 2024 |
| CYPRESS CAPITAL MANAGEMENT LLC (WY) | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| CORECAP ADVISORS, LLC | - | - | - | -133 | -100.00% | - | Jun 30, 2024 |
Brainstorm Cell Therapeutics's largest sold out institutional shareholder by shares sold is GSA CAPITAL PARTNERS LLP, sold -0.11M shares, valued at -, as of undefined.
Brainstorm Cell Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 0.04% | 22,317 | - | - | Mar 31, 2024 |
| Jacob Funds Inc. | 0.02% | 5,500 | - | - | Feb 29, 2024 |
| ETF Managers Trust | 0.01% | 114,318 | - | - | Dec 31, 2023 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 2,005 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 4,968 | - | - | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.01% | 74,691 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 44,535 | - | - | Mar 31, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 297,548 | - | - | Jan 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,352,385 | -401,014 | -22.87% | Mar 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 41,700 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 335,585 | 228,959 | 214.73% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 33,748 | - | - | Mar 31, 2024 |
| GPS Funds I | 0.00% | 4,802 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 2,356 | - | - | Mar 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 7,095 | - | - | Mar 31, 2024 |
| Meeder Funds | 0.00% | 2,513 | - | - | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 235 | - | - | Apr 30, 2021 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 13,057 | - | - | Mar 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 89,824 | - | - | Jan 31, 2024 |
| AdvisorShares Trust | 0.00% | 1,125 | - | - | Mar 28, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 11,287 | - | - | Feb 29, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 483 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 16,709 | - | - | Mar 28, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 5,700 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 897 | - | - | Mar 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 4,692 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 662 | - | - | Mar 31, 2024 |
| VALIC Co I | 0.00% | 14,477 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 98,934 | - | - | Feb 29, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 39,548 | - | - | Mar 31, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 3,614 | - | - | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 4,837 | - | - | Mar 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,000 | - | - | Mar 28, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 131,188 | - | - | Mar 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 3,892 | - | - | Jan 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 79,339 | - | - | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 4,006 | - | - | Jan 31, 2024 |
| Brighthouse Funds Trust II | 0.00% | 13,159 | - | - | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,464 | - | - | Feb 29, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 4,540 | - | - | Feb 29, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 3,299 | - | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 21,000 | - | - | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 105,374 | 22,958 | 27.86% | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 13,299 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 6,328 | - | - | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 12,147 | - | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 3,173 | - | - | Dec 31, 2023 |
| Bridge Builder Trust | 0.00% | 11,198 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 5,405 | - | - | Feb 29, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 3,565 | - | - | Mar 31, 2024 |
| John Hancock Funds II | 0.00% | 4,868 | - | - | Feb 29, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 6,300 | - | - | Feb 29, 2024 |
| BLACKROCK FUNDS | 0.00% | 1,759 | - | - | Mar 28, 2024 |
| VanEck ETF Trust | 0.00% | 10,444 | - | - | Jan 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 22 | - | - | Feb 29, 2024 |
| Advisors' Inner Circle Fund III | 0.00% | 15 | - | - | Jan 31, 2024 |
Brainstorm Cell Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 22.32K shares, compromising 0.04% of its total assets.
Brainstorm Cell Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 49 | 2.08% |
| 31 Mar, 24 | 48 | -4.00% |
| 31 Dec, 23 | 50 | -12.28% |
| 30 Sep, 23 | 57 | -10.94% |
| 30 Jun, 23 | 64 | 18.52% |
| 31 Mar, 23 | 54 | 10.20% |
| 31 Dec, 22 | 49 | 11.36% |
| 30 Sep, 22 | 44 | -6.38% |
| 30 Jun, 22 | 47 | 11.90% |
| 31 Mar, 22 | 42 | -4.55% |
| 31 Dec, 21 | 44 | -22.81% |
| 30 Sep, 21 | 57 | -5.00% |
| 30 Jun, 21 | 60 | -25.93% |
| 31 Mar, 21 | 81 | -17.35% |
| 31 Dec, 20 | 98 | 5.38% |
| 30 Sep, 20 | 93 | 6.90% |
| 30 Jun, 20 | 87 | 50.00% |
| 31 Mar, 20 | 58 | 28.89% |
| 31 Dec, 19 | 45 | 15.38% |
| 30 Sep, 19 | 39 | 2.63% |
| 30 Jun, 19 | 38 | -5.00% |
| 31 Mar, 19 | 40 | 17.65% |
| 31 Dec, 18 | 34 | -5.56% |
| 30 Sep, 18 | 36 | -10.00% |
| 30 Jun, 18 | 40 | 21.21% |
| 31 Mar, 18 | 33 | -5.71% |
| 31 Dec, 17 | 35 | -2.78% |
| 30 Sep, 17 | 36 | 33.33% |
| 30 Jun, 17 | 27 | 3.85% |
| 31 Mar, 17 | 26 | -3.70% |
| 31 Dec, 16 | 27 | 8.00% |
| 30 Sep, 16 | 25 | 13.64% |
| 30 Jun, 16 | 22 | -24.14% |
| 31 Mar, 16 | 29 | 26.09% |
| 31 Dec, 15 | 23 | 4.55% |
| 30 Sep, 15 | 22 | 15.79% |
| 30 Jun, 15 | 19 | -9.52% |
| 31 Mar, 15 | 21 | 110.00% |
| 31 Dec, 14 | 10 | 42.86% |
| 30 Sep, 14 | 7 | - |
As of 30 Jun 24, 49 institutions are holding Brainstorm Cell Therapeutics's shares, representing an increase of 2.08% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 12,057,911 | 210.44% |
| 31 Mar, 24 | 3,884,111 | 2.17% |
| 31 Dec, 23 | 3,801,493 | -17.96% |
| 30 Sep, 23 | 4,633,812 | -16.75% |
| 30 Jun, 23 | 5,566,350 | -10.25% |
| 31 Mar, 23 | 6,202,039 | 67.75% |
| 31 Dec, 22 | 3,697,087 | -4.50% |
| 30 Sep, 22 | 3,871,190 | -2.45% |
| 30 Jun, 22 | 3,968,427 | -4.58% |
| 31 Mar, 22 | 4,158,914 | -5.49% |
| 31 Dec, 21 | 4,400,270 | -14.26% |
| 30 Sep, 21 | 5,132,225 | -8.80% |
| 30 Jun, 21 | 5,627,617 | -32.99% |
| 31 Mar, 21 | 8,398,275 | 0.79% |
| 31 Dec, 20 | 8,332,209 | 22.59% |
| 30 Sep, 20 | 6,796,900 | 8.82% |
| 30 Jun, 20 | 6,245,803 | 68.42% |
| 31 Mar, 20 | 3,708,448 | 79.99% |
| 31 Dec, 19 | 2,060,379 | -2.04% |
| 30 Sep, 19 | 2,103,250 | 9.79% |
| 30 Jun, 19 | 1,915,781 | -20.21% |
| 31 Mar, 19 | 2,400,972 | -1.53% |
| 31 Dec, 18 | 2,438,173 | 3.49% |
| 30 Sep, 18 | 2,355,890 | -2.79% |
| 30 Jun, 18 | 2,423,453 | 45.41% |
| 31 Mar, 18 | 1,666,583 | -7.82% |
| 31 Dec, 17 | 1,807,991 | -26.30% |
| 30 Sep, 17 | 2,453,306 | 2.62% |
| 30 Jun, 17 | 2,390,616 | 133.06% |
| 31 Mar, 17 | 1,025,740 | -33.88% |
| 31 Dec, 16 | 1,551,333 | 18.17% |
| 30 Sep, 16 | 1,312,816 | -19.46% |
| 30 Jun, 16 | 1,629,959 | -5.29% |
| 31 Mar, 16 | 1,720,940 | 14.98% |
| 31 Dec, 15 | 1,496,671 | -76.84% |
| 30 Sep, 15 | 6,462,258 | 260.11% |
| 30 Jun, 15 | 1,794,506 | -25.48% |
| 31 Mar, 15 | 2,408,050 | 2246.43% |
| 31 Dec, 14 | 102,626 | -88.81% |
| 30 Sep, 14 | 917,450 | - |
Brainstorm Cell Therapeutics (BCLI) has 12.06M shares outstanding as of 30 Jun 24, up 210.44% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 18.63% | 51.74% |
| 31 Mar, 24 | 6.00% | 7.70% |
| 31 Dec, 23 | 8.83% | 8.05% |
| 30 Sep, 23 | 10.47% | 5.33% |
| 30 Jun, 23 | 14.02% | 4.92% |
| 31 Mar, 23 | 16.88% | 16.59% |
| 31 Dec, 22 | 10.09% | 8.96% |
| 30 Sep, 22 | 10.61% | 8.97% |
| 30 Jun, 22 | 10.88% | 8.35% |
| 31 Mar, 22 | 11.41% | 7.55% |
| 31 Dec, 21 | 12.29% | 6.15% |
| 30 Sep, 21 | 14.14% | 5.89% |
| 30 Jun, 21 | 15.50% | 2.81% |
| 31 Mar, 21 | 23.46% | 4.33% |
| 31 Dec, 20 | 23.28% | 4.89% |
| 30 Sep, 20 | 21.82% | 4.79% |
| 30 Jun, 20 | 21.34% | 12.53% |
| 31 Mar, 20 | 13.05% | 24.83% |
| 31 Dec, 19 | 7.25% | 8.12% |
| 30 Sep, 19 | 9.45% | 12.13% |
| 30 Jun, 19 | 8.83% | 6.70% |
| 31 Mar, 19 | 11.48% | 8.30% |
| 31 Dec, 18 | 11.76% | 9.07% |
| 30 Sep, 18 | 11.39% | 7.38% |
| 30 Jun, 18 | 12.42% | 16.23% |
| 31 Mar, 18 | 8.75% | 9.44% |
| 31 Dec, 17 | 9.63% | 5.64% |
| 30 Sep, 17 | 13.06% | 8.02% |
| 30 Jun, 17 | 12.76% | 42.35% |
| 31 Mar, 17 | 5.49% | 7.97% |
| 31 Dec, 16 | 8.30% | 16.76% |
| 30 Sep, 16 | 7.04% | 9.22% |
| 30 Jun, 16 | 8.74% | 10.27% |
| 31 Mar, 16 | 9.23% | 14.17% |
| 31 Dec, 15 | 8.07% | 0.66% |
| 30 Sep, 15 | 34.97% | 36.96% |
| 30 Jun, 15 | 9.73% | 5.51% |
| 31 Mar, 15 | 13.28% | 2939.71% |
| 31 Dec, 14 | 0.67% | 1.84% |
| 30 Sep, 14 | 6.05% | - |
As of 30 Jun 24, Brainstorm Cell Therapeutics is held by 18.63% institutional shareholders, representing a 51.74% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 20 | 66.67% |
| 31 Mar, 24 | 12 | -29.41% |
| 31 Dec, 23 | 17 | -32.00% |
| 30 Sep, 23 | 25 | - |
| 30 Jun, 23 | 25 | 25.00% |
| 31 Mar, 23 | 20 | 25.00% |
| 31 Dec, 22 | 16 | -11.11% |
| 30 Sep, 22 | 18 | 12.50% |
| 30 Jun, 22 | 16 | 6.67% |
| 31 Mar, 22 | 15 | - |
| 31 Dec, 21 | 15 | 7.14% |
| 30 Sep, 21 | 14 | -33.33% |
| 30 Jun, 21 | 21 | -40.00% |
| 31 Mar, 21 | 35 | -33.96% |
| 31 Dec, 20 | 53 | 15.22% |
| 30 Sep, 20 | 46 | -22.03% |
| 30 Jun, 20 | 59 | 47.50% |
| 31 Mar, 20 | 40 | 135.29% |
| 31 Dec, 19 | 17 | 13.33% |
| 30 Sep, 19 | 15 | 15.38% |
| 30 Jun, 19 | 13 | -23.53% |
| 31 Mar, 19 | 17 | 41.67% |
| 31 Dec, 18 | 12 | 9.09% |
| 30 Sep, 18 | 11 | -54.17% |
| 30 Jun, 18 | 24 | 118.18% |
| 31 Mar, 18 | 11 | -42.11% |
| 31 Dec, 17 | 19 | -5.00% |
| 30 Sep, 17 | 20 | 66.67% |
| 30 Jun, 17 | 12 | -25.00% |
| 31 Mar, 17 | 16 | 45.45% |
| 31 Dec, 16 | 11 | 37.50% |
| 30 Sep, 16 | 8 | 100.00% |
| 30 Jun, 16 | 4 | -71.43% |
| 31 Mar, 16 | 14 | 75.00% |
| 31 Dec, 15 | 8 | - |
| 30 Sep, 15 | 8 | 14.29% |
| 30 Jun, 15 | 7 | -58.82% |
| 31 Mar, 15 | 17 | 112.50% |
| 31 Dec, 14 | 8 | 14.29% |
| 30 Sep, 14 | 7 | - |
20 institutional shareholders have increased their position in BCLI stock as of 30 Jun 24 compared to 12 in the previous quarter (a 66.67% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 9 | -18.18% |
| 31 Mar, 24 | 11 | -8.33% |
| 31 Dec, 23 | 12 | - |
| 30 Sep, 23 | 12 | -7.69% |
| 30 Jun, 23 | 13 | 62.50% |
| 31 Mar, 23 | 8 | -33.33% |
| 31 Dec, 22 | 12 | 20.00% |
| 30 Sep, 22 | 10 | -33.33% |
| 30 Jun, 22 | 15 | 50.00% |
| 31 Mar, 22 | 10 | -23.08% |
| 31 Dec, 21 | 13 | -50.00% |
| 30 Sep, 21 | 26 | - |
| 30 Jun, 21 | 26 | 4.00% |
| 31 Mar, 21 | 25 | 13.64% |
| 31 Dec, 20 | 22 | 22.22% |
| 30 Sep, 20 | 18 | 38.46% |
| 30 Jun, 20 | 13 | 1200.00% |
| 31 Mar, 20 | 1 | -90.00% |
| 31 Dec, 19 | 10 | 66.67% |
| 30 Sep, 19 | 6 | 20.00% |
| 30 Jun, 19 | 5 | - |
| 31 Mar, 19 | 5 | 66.67% |
| 31 Dec, 18 | 3 | -57.14% |
| 30 Sep, 18 | 7 | 250.00% |
| 30 Jun, 18 | 2 | -66.67% |
| 31 Mar, 18 | 6 | 50.00% |
| 31 Dec, 17 | 4 | 100.00% |
| 30 Sep, 17 | 2 | -50.00% |
| 30 Jun, 17 | 4 | 33.33% |
| 31 Mar, 17 | 3 | - |
| 31 Dec, 16 | 3 | 50.00% |
| 30 Sep, 16 | 2 | -50.00% |
| 30 Jun, 16 | 4 | - |
| 31 Mar, 16 | 4 | 33.33% |
| 31 Dec, 15 | 3 | 50.00% |
| 30 Sep, 15 | 2 | -60.00% |
| 30 Jun, 15 | 5 | 400.00% |
| 31 Mar, 15 | 1 | - |
| 31 Dec, 14 | - | - |
| 30 Sep, 14 | - | - |
9 institutional shareholders have reduced their position in BCLI stock as of 30 Jun 24 compared to 11 in the previous quarter (a -18.18% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 49 | 2.08% | 12,057,911 | 210.44% | 18.63% | 51.74% | 20 | 66.67% | 9 | -18.18% |
| 31 Mar, 24 | 48 | -4.00% | 3,884,111 | 2.17% | 6.00% | 7.70% | 12 | -29.41% | 11 | -8.33% |
| 31 Dec, 23 | 50 | -12.28% | 3,801,493 | -17.96% | 8.83% | 8.05% | 17 | -32.00% | 12 | - |
| 30 Sep, 23 | 57 | -10.94% | 4,633,812 | -16.75% | 10.47% | 5.33% | 25 | - | 12 | -7.69% |
| 30 Jun, 23 | 64 | 18.52% | 5,566,350 | -10.25% | 14.02% | 4.92% | 25 | 25.00% | 13 | 62.50% |
| 31 Mar, 23 | 54 | 10.20% | 6,202,039 | 67.75% | 16.88% | 16.59% | 20 | 25.00% | 8 | -33.33% |
| 31 Dec, 22 | 49 | 11.36% | 3,697,087 | -4.50% | 10.09% | 8.96% | 16 | -11.11% | 12 | 20.00% |
| 30 Sep, 22 | 44 | -6.38% | 3,871,190 | -2.45% | 10.61% | 8.97% | 18 | 12.50% | 10 | -33.33% |
| 30 Jun, 22 | 47 | 11.90% | 3,968,427 | -4.58% | 10.88% | 8.35% | 16 | 6.67% | 15 | 50.00% |
| 31 Mar, 22 | 42 | -4.55% | 4,158,914 | -5.49% | 11.41% | 7.55% | 15 | - | 10 | -23.08% |
| 31 Dec, 21 | 44 | -22.81% | 4,400,270 | -14.26% | 12.29% | 6.15% | 15 | 7.14% | 13 | -50.00% |
| 30 Sep, 21 | 57 | -5.00% | 5,132,225 | -8.80% | 14.14% | 5.89% | 14 | -33.33% | 26 | - |
| 30 Jun, 21 | 60 | -25.93% | 5,627,617 | -32.99% | 15.50% | 2.81% | 21 | -40.00% | 26 | 4.00% |
| 31 Mar, 21 | 81 | -17.35% | 8,398,275 | 0.79% | 23.46% | 4.33% | 35 | -33.96% | 25 | 13.64% |
| 31 Dec, 20 | 98 | 5.38% | 8,332,209 | 22.59% | 23.28% | 4.89% | 53 | 15.22% | 22 | 22.22% |
| 30 Sep, 20 | 93 | 6.90% | 6,796,900 | 8.82% | 21.82% | 4.79% | 46 | -22.03% | 18 | 38.46% |
| 30 Jun, 20 | 87 | 50.00% | 6,245,803 | 68.42% | 21.34% | 12.53% | 59 | 47.50% | 13 | 1200.00% |
| 31 Mar, 20 | 58 | 28.89% | 3,708,448 | 79.99% | 13.05% | 24.83% | 40 | 135.29% | 1 | -90.00% |
| 31 Dec, 19 | 45 | 15.38% | 2,060,379 | -2.04% | 7.25% | 8.12% | 17 | 13.33% | 10 | 66.67% |
| 30 Sep, 19 | 39 | 2.63% | 2,103,250 | 9.79% | 9.45% | 12.13% | 15 | 15.38% | 6 | 20.00% |
| 30 Jun, 19 | 38 | -5.00% | 1,915,781 | -20.21% | 8.83% | 6.70% | 13 | -23.53% | 5 | - |
| 31 Mar, 19 | 40 | 17.65% | 2,400,972 | -1.53% | 11.48% | 8.30% | 17 | 41.67% | 5 | 66.67% |
| 31 Dec, 18 | 34 | -5.56% | 2,438,173 | 3.49% | 11.76% | 9.07% | 12 | 9.09% | 3 | -57.14% |
| 30 Sep, 18 | 36 | -10.00% | 2,355,890 | -2.79% | 11.39% | 7.38% | 11 | -54.17% | 7 | 250.00% |
| 30 Jun, 18 | 40 | 21.21% | 2,423,453 | 45.41% | 12.42% | 16.23% | 24 | 118.18% | 2 | -66.67% |
| 31 Mar, 18 | 33 | -5.71% | 1,666,583 | -7.82% | 8.75% | 9.44% | 11 | -42.11% | 6 | 50.00% |
| 31 Dec, 17 | 35 | -2.78% | 1,807,991 | -26.30% | 9.63% | 5.64% | 19 | -5.00% | 4 | 100.00% |
| 30 Sep, 17 | 36 | 33.33% | 2,453,306 | 2.62% | 13.06% | 8.02% | 20 | 66.67% | 2 | -50.00% |
| 30 Jun, 17 | 27 | 3.85% | 2,390,616 | 133.06% | 12.76% | 42.35% | 12 | -25.00% | 4 | 33.33% |
| 31 Mar, 17 | 26 | -3.70% | 1,025,740 | -33.88% | 5.49% | 7.97% | 16 | 45.45% | 3 | - |
| 31 Dec, 16 | 27 | 8.00% | 1,551,333 | 18.17% | 8.30% | 16.76% | 11 | 37.50% | 3 | 50.00% |
| 30 Sep, 16 | 25 | 13.64% | 1,312,816 | -19.46% | 7.04% | 9.22% | 8 | 100.00% | 2 | -50.00% |
| 30 Jun, 16 | 22 | -24.14% | 1,629,959 | -5.29% | 8.74% | 10.27% | 4 | -71.43% | 4 | - |
| 31 Mar, 16 | 29 | 26.09% | 1,720,940 | 14.98% | 9.23% | 14.17% | 14 | 75.00% | 4 | 33.33% |
| 31 Dec, 15 | 23 | 4.55% | 1,496,671 | -76.84% | 8.07% | 0.66% | 8 | - | 3 | 50.00% |
| 30 Sep, 15 | 22 | 15.79% | 6,462,258 | 260.11% | 34.97% | 36.96% | 8 | 14.29% | 2 | -60.00% |
| 30 Jun, 15 | 19 | -9.52% | 1,794,506 | -25.48% | 9.73% | 5.51% | 7 | -58.82% | 5 | 400.00% |
| 31 Mar, 15 | 21 | 110.00% | 2,408,050 | 2246.43% | 13.28% | 2939.71% | 17 | 112.50% | 1 | - |
| 31 Dec, 14 | 10 | 42.86% | 102,626 | -88.81% | 0.67% | 1.84% | 8 | 14.29% | - | - |
| 30 Sep, 14 | 7 | - | 917,450 | - | 6.05% | - | 7 | - | - | - |
Brainstorm Cell Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Brainstorm Cell Therapeutics's stock was made by Dagher Ibrahim B. on Jul 24 2024, selling 63,000 shares at $0.35 per share (valued at $22.07K). The last insider buy of BCLI was made by Lebovits Chaim on Jul 31 2024, buying 15,000 shares at $0.52 per share (worth $7.77K).
Brainstorm Cell Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 13 | 1 | 1300.00% |
| Q1 2024 | 4 | - | - |
| Q3 2023 | 3 | - | - |
| Q2 2023 | 5 | - | - |
| Q4 2022 | 1 | - | - |
| Q3 2022 | 1 | - | - |
| Q2 2022 | 1 | - | - |
| Q1 2022 | 2 | - | - |
| Q4 2021 | 15 | - | - |
| Q3 2021 | - | 2 | - |
| Q4 2020 | 1 | 1 | 100.00% |
| Q3 2020 | 5 | 5 | 100.00% |
| Q2 2020 | 6 | - | - |
| Q1 2020 | 3 | 1 | 300.00% |
| Q4 2019 | 8 | - | - |
| Q3 2019 | 6 | 2 | 300.00% |
| Q1 2019 | 3 | - | - |
| Q4 2018 | 7 | 1 | 700.00% |
| Q3 2018 | 2 | 1 | 200.00% |
| Q1 2018 | 8 | - | - |
13 total buy trades, and 1 total sell trades (buy/sell ratio of 13.00%) were made by Brainstorm Cell Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | - | - |
| Q1 2024 | - | - | - |
| Q3 2023 | 1 | - | - |
| Q2 2023 | - | - | - |
| Q4 2022 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | - | - |
| Q3 2021 | - | - | - |
| Q4 2020 | 1 | - | - |
| Q3 2020 | 2 | 5 | 40.00% |
| Q2 2020 | - | - | - |
| Q1 2020 | - | - | - |
| Q4 2019 | 3 | - | - |
| Q3 2019 | - | 1 | - |
| Q1 2019 | 1 | - | - |
| Q4 2018 | - | - | - |
| Q3 2018 | - | - | - |
| Q1 2018 | 2 | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Brainstorm Cell Therapeutics's stocks.
Brainstorm Cell Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| CKPT | Checkpoint Therapeutics, Inc. |
| GRI | GRI Bio, Inc. |
| CUE | Cue Biopharma, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| GMDA | Gamida Cell Ltd. |
| DBTX | Decibel Therapeutics, Inc. |
| MREO | Mereo BioPharma Group plc |
| ALDX | Aldeyra Therapeutics, Inc. |
| BCAB | BioAtla, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| GBIO | Generation Bio Co. |
| CRVS | Corvus Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| PASG | Passage Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| TRVI | Trevi Therapeutics, Inc. |
| LIFE | aTyr Pharma, Inc. |
| CELC | Celcuity Inc. |
BCLI Ownership FAQ
Who Owns Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics is owned by institutional shareholders (18.63%), insiders (9.00%), and public (72.38%). The largest institutional shareholder of Brainstorm Cell Therapeutics is ARMISTICE CAPITAL, LLC (12.23% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.04% of total shares).
Who are the major institutional shareholders of Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics's major institutional shareholders are ARMISTICE CAPITAL, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BLACKROCK INC., and LIBERTY WEALTH MANAGEMENT LLC. The top five shareholders own together 16.43% of the company's share outstanding.
How many Brainstorm Cell Therapeutics shareholders are there?
As of Jun 2024, there are 49 institutional shareholders of Brainstorm Cell Therapeutics.
What percentage of Brainstorm Cell Therapeutics is owned by ARMISTICE CAPITAL, LLC?
ARMISTICE CAPITAL, LLC owns 7.92M shares of Brainstorm Cell Therapeutics, representing 12.23% of the company's total shares outstanding, valued at $2.68M (as of Jun 2024).
What percentage of Brainstorm Cell Therapeutics is owned by VANGUARD GROUP INC?
As of Jun 2024, VANGUARD GROUP INC holds 1.51M shares of Brainstorm Cell Therapeutics (BCLI), compromising 2.33% of the company, valued at $511.35K.
What percentage of Brainstorm Cell Therapeutics is owned by GEODE CAPITAL MANAGEMENT, LLC?
GEODE CAPITAL MANAGEMENT, LLC is the third largest holder of Brainstorm Cell Therapeutics. The company owns 484.28K of the company's shares outstanding (worth $163.99K).